DelMar Pharmaceuticals Inc (NASDAQ:DMPI) has earned an average broker rating score of 1.50 (Buy) from the four brokers that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a hold recommendation and three have assigned a strong buy recommendation to the company.

Brokers have set a 12-month consensus target price of $11.16 for the company and are predicting that the company will post ($0.15) earnings per share for the current quarter, according to Zacks. Zacks has also given DelMar Pharmaceuticals an industry rank of 186 out of 265 based on the ratings given to related companies.

Separately, HC Wainwright set a $12.00 price target on DelMar Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, October 16th.

Shares of DelMar Pharmaceuticals (NASDAQ DMPI) opened at $1.30 on Friday. DelMar Pharmaceuticals has a 12 month low of $0.78 and a 12 month high of $5.39.

An institutional investor recently bought a new position in DelMar Pharmaceuticals stock. Susquehanna International Group LLP purchased a new position in DelMar Pharmaceuticals Inc (NASDAQ:DMPI) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 364,496 shares of the company’s stock, valued at approximately $306,000. Susquehanna International Group LLP owned 1.69% of DelMar Pharmaceuticals as of its most recent SEC filing. 17.03% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Zacks: DelMar Pharmaceuticals Inc (DMPI) Given $11.16 Consensus Target Price by Brokerages” was first posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this story on another site, it was copied illegally and reposted in violation of international copyright and trademark laws. The correct version of this story can be viewed at

DelMar Pharmaceuticals Company Profile

DelMar Pharmaceuticals, Inc is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer.

Get a free copy of the Zacks research report on DelMar Pharmaceuticals (DMPI)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for DelMar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals and related companies with's FREE daily email newsletter.